... by small cells with a very high nucleus/cytoplasm ratio Histological examination of mice lungs showed the occurrence of multiple dysplastic foci of clustering small cells in the bronchial and ... minor percentage brain, liver and pancreas metastases were observed Inactivation of p53 and pRB occurs in the majority of neuroendocrine lung carcinomas in humans and these observations strongly ... probably causes lung cancer in our transgenic model, through the inactivation of p53 and pRB The transgenic lungcarcinoma progress to multiple and bilateral tumors with histopathology and immunophenotype...
... Non -small- celllung cancer: Cancer and Leukemia Group B J Clin Oncol 2007, 25:1698-704 Belani CP, Barstis J, Perry MC, et al: Multicenter, randomized trial for stage IIIB or IV non -small celllung ... Clin Lung Cancer 2006, 8:116-21 Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non -small celllung cancer: a randomized ... received both doses of carboplatin (AUC = 6), and 13 of 14 patients completed their full course of radiotherapy All 14 patients received at least of four planned courses of pemetrexed (7 of 14 received...
... Impact of large tumor size on survival after resection of pathologically node negative (pN0) non -small celllung cancer 2005 18 Detterbeck FC, Boffa DJ, Tanoue LT: The new lung cancer staging ... non -small celllung cancer: results of a prospective trial Lung Cancer 2010, 68:72-77 Shen Y, Zhang H, Wang J, Zhong R, Jiang X, Xu Q, Wang X, Bai S, Xu F: Hypofractionated radiotherapy for lung ... multi-center randomized trial of limited-disease smallcelllung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202 Radiation Oncology 2009, 11 Ball D: Stereotactic radiotherapy for nonsmall cell...
... thoracotomy and therefore they were denied of the benefit that radical resection can offer in long term survival Therefore the role of surgery in the integrated management ofsmallcelllung cancer ... question raised and on which was based this review is whether the adjunction of surgery in the smallcelllungcarcinoma' s management may influence the outcome of specific subset of patients We ... Scadding JG: Medical research council comparative trial of surgery and radiotherapy for primary treatment ofsmallcell or oat -cell carcinomaof the bronchus Ten year follow up Lancet 1973, 2:63-65...
... (PLE) which is a rather rare cause of seizures in patients with non -small celllungcarcinoma Case presentation Stage IV (T4N2M0) undifferentiated large celllungcarcinoma was diagnosed in a 64-year-old ... Paraneoplastic syndromes occur in 10–20% of patients with lung cancer Smallcelllung cancer (SCLC) is associated with the greatest frequency and diversity of paraneoplastic syndromes, including Cushing's ... of less than years) between the onset of neurological symptoms and diagnosis oflung cancer PLE usually precedes the diagnosis of cancer by a median time of months, but may also appear after tumor...
... in NSCLC cell lines than in normal lung cells A Fold change of UCH-L1 mRNA in lung cancer cell lines compared to the normal lungcell line BEAS-2B (n = 3) B Densitometry of the level of UCH-L1 ... siRNA in both squamous cellcarcinoma (H157) and adenocarcinoma (H838) cell lines Knockdown of UCH-L1 in H838 cells shows morphological differences indicative of apoptosis andcell death was confirmed ... expressed in lung squamous cell carcinoma, and NSCLC cell line studies show that increased UCH-L1 expression causes apoptotic resistance in H838 adenocarcinoma cells and a greater capacity for cell migration...
... monoxide of normal lung exposed to 13 Gy or higher, and suggested that a small dose of radiation to a large volume oflung could be much worse than a large dose to a small volume in functional lung ... patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/ or concurrent chemotherapy and radiotherapy for locally advanced nonsmall -cell carcinomaof the lung ... correlated with percentage oflung volume receiving 20 Gy (V20) or 30 Gy (V30), with NTCP and MLD SARP occurred in 45% and 37% of patients with MLD of more than 15 Gy and NTCP of 50% or more, respectively,...
... (adenocarcinoma) and one from an adenoidcystic carcinoma The CTV for the NSCLC that relapsed were 55 cm3(large cell carcinoma) and 32 cm3 (squamous cell carcinoma) At present, as the number of relapses ... non -small celllungcarcinoma (n = 10), breast cancer (n = 6), ENT (n = 3), other origin (n = 3) Biopsies of bronchial carcinomas exhibited the following histological results: squamous cellcarcinoma ... experience of this approach is scanty Results of single-dose irradiation oflung tumors have been published by Hara et al [14] and Hof et al [15] – studies involving patient collectives of 19 and 10...
... squamous cell Page of carcinomas Our data showed that the KRAS mutations were detected in the primary tumor of one adenocarcinoma and also in six metastatic tumors (five squamous cell carcinomas and ... PCR Amplification and sequencing The two codons of KRAS (12 and 13) and two exons of EGFR (19 and 21) were amplified by PCR using the following forward and reverse primers: exon of KRAS: 5’AAAGGTACTGGTGGAGTATTTGATAGTG-3’, ... the treatment of patients with NSCLC Materials and methods Page of amount of tumor cells in order to ensure that they contained more than 70% of tumor components for DNA extraction and mutation...
... white blood cells (WBC) count of at least 3, 000/μL, platelet count of at least 100, 000 μL, hemoglobin of at least 10 g/dl, life expectancy of at least months, and creatinine, bilirubin, and transaminase ... Management of unfit older patients with advanced NSCLC Cancer Treatment Reviews 2009, 35:517-521 Gérard C, Debruyne C: Immunotherapy in the landscape of new targeted treatments for non -small celllung ... nonsmall -cell lung cancer (FLEX): an open-label randomized phase III trial Lancet 2009, 373(9674):1525-31 Rodríguez PC, Rodríguez G, González G, Lage A: Clinical development and perspectives of...
... RDI was ≥ 85% in 59% and 68%, and < 50% in only 5% and 8% of arm A and B patients, respectively Gemcitabine RDI was ≥ 85% in 33% and 74%, and < 50% in 23% and 0% of arm A and B patients, respectively ... Fairclough D, Cella D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D: Comparison of survival and quality of life in advanced non -small- celllung cancer patients treated with two dose levels of paclitaxel ... prolong survival and improve quality of life in non -small celllung cancer: a review of the literature and future directions Clin Cancer Res 1998, 4:1087-1100 Le Chevalier T, Brisgand D, Douillard...
... [13]: undifferentiated large cell carcinomas andsmallcell neuroendocrine carcinomas, squamous cellcarcinomaand 69 adenocarcinomas, of which 55 showed a single pattern and 14 presented mixed aspects ... sensitivity of 84.6% and a specificity of 98.9% for E746-A750 and a sensitivity of 95.2% and a specificity of 98.8% for L858R Kitamura et al [22] reported a sensitivity of 36% and a specificity of 97% ... showing scoring of IHC staining of human NSCLC cell lines andlung cancer patient tumor tissues A score of was considered negative, a score of was considered weakly positive, and a score of or was...
... impact of angiogenic marker expression in tumor cells versus stromal cells in non smallcelllung cancer Clin Cancer Res 2007, 13:6649-57 World Health Organization: Histological Typing ofLungand ... prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non -small celllung cancer Anticancer Res 2009, 29:4175-83 Al-Saad S, Al-Shibli K, Donnem T, Andersen ... 4:578-85 33 Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM: Prognostic impact of Notch ligands and receptors in nonsmall celllung cancer: coexpression of Notch-1 and vascular endothelial...
... copies per cell in ≥10% cells) ≤2 copies in >90% of cells ≤2 copies in ≥40% of cells, copies in 10%–40% of the cells, ≥4 copies in 90% of cells ≤2 copies in ≥40% of cells, copies in 10%–40% of the cells, ≥4 copies in
... squamous celland small- cell anaplastic carcinomaof the larynx Otolaryngol Head Neck Surg 1986, 95:99-103 Gnepp DR: Smallcell neuroendocrine carcinomaof the larynx A critical review of the literature ... http://www.wjso.com/content/8/1/92 Page of Figure A Histologic appearance of combinations of small, ductal and squamous cellular components of the tumor (H & E, x100) B Transitional area between squamous cellcarcinomaand neuroendocrine ... Block LJ: Smallcellcarcinomaof the nose and paranasal sinuses Otolaryngol Head Neck Surg 1982, 90:516-517 Avitia S, Osborne RF: Blindness: a sequela of sinonasal smallcell neuroendocrine carcinoma...
... Stereotactic body radiotherapy for stage I lung cancer andsmalllung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results Radiat Oncol ... Adenocarcinoma 66 46 18 Squamous cellcarcinoma 35 19 16 Unclassified NSCLC 13 10 Unproven 10 10 Tumor location Central 29 18 11 Peripheral 95 67 26 Abbreviations: NSCLC = non -small celllung ... M, Hara R, Itami J, Yamada K, Araki T: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non -small celllung cancer: updated results of 257 patients in a Japanese multi-institutional...
... growth properties, and morphological characteristics of permanent human smallcelllung cancer cell lines J Cancer Res Clin Oncol 1987, 113:31-40 NCCN guidelines for small- celllung cancer [http://www.nccn.org/ ... C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF: Five compared with six fractions per week of conventional radiotherapy of squamous -cell carcinomaof head and ... in lung cancer: small- celllung cancer (SCLC) Int J Radiat Oncol Biol Phys 2008, 72:327-334 Roof KS, Fidias P, Lynch TJ, Choi NC: Radiation dose intensification in limited-stage small- cell lung...
... of offered Researchers from the University of Chicago analyzed the patterns of recurrence among 38 patients with stage IIIB and IV NSCLC who were enrolled on a Phase II trial of oxaliplatin and ... course of their cancer treatment, and 22 patients underwent prior resection of their primary lung mass Thirteen patients had curative resection of a metastatic lesion prior to their course of SBRT ... USA Authors’ contributions PC and SM participated in creation of database and input of data PC drafted manuscript JM and PEC performed the statistical analysis YC, PO and MT treated the patients...
... for type A models, a standard fractionation schedule of fractions of 20 Gy or fractions of 18 Gy and a conservative fractionation schedule of fractions of 12 Gy or fractions of 11 Gy could be allowed ... Amsterdam and the Dutch Lung Cancer Research Group The primary study objectives are to compare local and regional control, quality of life and treatment costs at and years in patients who are randomized ... I tumours and Percent oflung (both lungs minus GTV) receiving 20 Gy or more (V20 Gy) from a total of 22 patients with stage I tumours and patients with stage 1B tumours (with PTVs of 59 cc,...
... Concannon JP, Rotman M: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cellcarcinomaof the lung: report by the Radiation ... Cardiovascular disease Smoker Pathologic classification (%) Adenocarcinoma Squamous cellcarcinoma Large cellcarcinoma Mixed Non -small cell not otherwise specified Grade (%) Well-differentiated Moderately ... changed since RTOG 7301 established standard irradiation doses and volumes (including ENI): the advent of CT-based 3D-CRT, the use of chemotherapy, and better stagingand target delineation using PET...